Boehringer Ingelheim
Sergio Trombetta is a seasoned researcher in cancer immunology and immune modulation, currently serving as a Senior Principal Scientist at Boehringer Ingelheim since March 2017. Prior experience includes roles as Principal Scientist in Translational Medicine at Celldex Therapeutics and Kolltan Pharmaceuticals, as well as an Assistant Professor at New York University for eight years. Notable expertise encompasses mouse models of inflammation, innate immunity, and tumor immunology, alongside proficiency in genomic analysis of rare cell populations. Previous positions at the Ludwig Institute for Cancer Research and Yale University School of Medicine showcased advanced skills in protein localization, antibody characterization, and immunogen design. Academically, Sergio Trombetta holds a PhD in Biochemistry and Molecular Biology and a PharmD in Pharmacology from the University of Buenos Aires, Argentina.
This person is not in any teams
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.